Physostigmine

A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.

Also Known As:

Networked: 801 relevant articles (54 outcomes, 76 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Hofer, Stefan: 4 articles (07/2015 - 04/2010)
2.	Weigand, Markus A: 3 articles (07/2015 - 04/2010)
3.	Schmidt, Karsten: 3 articles (03/2015 - 04/2010)
4.	Hur, Gyeung-Haeng: 3 articles (01/2012 - 01/2002)
5.	Greig, Nigel H: 3 articles (07/2010 - 02/2005)
6.	Wetherell, Janet: 3 articles (04/2007 - 09/2002)
7.	Kim, Yun-Bae: 3 articles (11/2005 - 01/2002)
8.	Brenner, Thorsten: 2 articles (07/2015 - 01/2015)
9.	Lehmann, Christian: 2 articles (04/2015 - 01/2014)
10.	Chattopadhyay, Pronobesh: 2 articles (06/2014 - 07/2013)

Related Diseases

1.	Poisoning 02/01/1993 - "Efficacy of physostigmine as a pretreatment for organophosphate poisoning." 01/01/1991 - "This protected enzyme became available as the physostigmine was eliminated from the body after 60-120 min. Animals exhibited mild signs of poisoning, such as hyperactivity and chewing, during the first 30-60 min, after which they recovered. " 03/01/2011 - "Therefore, treatment of OP poisoning with a carbamate, such as physostigmine, should be carefully re-evaluated." 03/01/2011 - "Physostigmine (0.8 mg/kg im) at 1 min after poisoning increased mortality. " 01/01/2009 - "The recommendations of the Swiss Toxicological Information Centre were followed and physostigmine, the antidote for severe poisoning when 10 or more berries are ingested, was not administered. "
2.	Alzheimer Disease (Alzheimer's Disease) 05/01/1984 - "Subcutaneous or intravenous administration of physostigmine improved the copying of geometric figures in three out of six patients with presumed Alzheimer's disease who showed a remarkable constructional disturbance. " 01/01/1990 - "Along with other studies in the literature, this study casts serious doubt on the efficacy of short-term administration of oral physostigmine when used alone in an attempt to ameliorate cognitive dysfunction in Alzheimer's disease patients. " 01/01/1985 - "To examine the efficacy of cholinergic enhancement in senile dementia of the Alzheimer type (SDAT), oral physostigmine was given to eight patients in a cross-over trial of three dose levels and a matching placebo. " 01/01/1994 - "Physostigmine has been reported to improve the memory function of some patients with Alzheimer's Disease (AD). " 04/01/1993 - "Physostigmine ameliorates the delusions of Alzheimer's disease."
3.	Seizures (Seizure) 02/01/2002 - "Although physostigmine is considered an acceptable antidote for severe DPH toxicity, adverse effects such as seizures and cholinergic crisis may occur. " 01/01/1990 - "In two infants who had frequent clinical seizures, the seizures were temporarily blocked by physostigmine. " 02/25/1984 - "In six patients seizures were precipitated by physostigmine. " 02/01/1981 - "General supportive care and seizure control with physostigmine resulted in complete recovery within 72 hours. " 01/01/1980 - "dose of physostigmine sulfate (1.0 mg/kg) resulted in 90% mortality among male rats following a pronounced cholinergic syndrome, including convulsions. "
4.	Dementia (Dementias) 01/01/1985 - "Efficacy of oral physostigmine in primary degenerative dementia. " 01/01/2001 - "All relevant unconfounded, double-blind, randomized, placebo-controlled trials in which physostigmine was administered for more than one day to patients with dementia of Alzheimer type. " 01/01/2001 - "Studies conducted more than 20 years ago suggested that physostigmine could improve memory in people with or without dementia. " 01/01/1990 - "Oral physostigmine as treatment for dementia of the Alzheimer type: a long-term outpatient trial." 01/01/1990 - "Oral physostigmine as treatment for primary degenerative dementia: a double-blind placebo-controlled inpatient trial."
5.	Memory Disorders (Memory Loss) 02/01/2008 - "Physostigmine (50 microg/kg) fully reversed memory deficits in the Ts65Dn mice in the 4-month-old group but not in older mice. " 04/01/1985 - "Physostigmine reverses memory deficits produced by pretraining electrical stimulation of the dorsal hippocampus in mice." 04/01/1985 - "Learning and memory deficits after lesions of the nucleus basalis magnocellularis: reversal by physostigmine." 03/01/1982 - "Physostigmine in the treatment of memory disorders: a case report." 11/01/1992 - "These two drugs had little effect on memory deficits brought about by medial septum or fimbria-fornix lesioning, whereas physostigmine ameliorated these deficits in scopolamine-treated and medial septum-lesioned rats, but not in fimbria-fornix-lesioned rats. "

Related Drugs and Biologics

1.	Soman
2.	Cholinesterases (Cholinesterase)
3.	Scopolamine (Hyoscine)
4.	Atropine (Hyoscyamine)
5.	donepezil (Aricept)
6.	Acetylcholinesterase
7.	Tacrine (Cognex)
8.	Arecoline (Arecolin)
9.	Acetylcholine (Acetylcholine Chloride)
10.	Lecithins

Related Therapies and Procedures

1.	Intravenous Infusions
2.	Intravenous Injections
3.	Oral Administration
4.	Injections
5.	Induced Hypothermia